Teva’s Austedo XR Approved for Tardive Dyskinesia and Huntington’s Disease-Associated Chorea

Teva Pharmaceuticals has received FDA approval for its Austedo XR (deutetrabenazine) extended-release tablets for adults with tardive dyskinesia and chorea associated with Huntington’s disease.

The extended-release version of the drug for once-daily use has demonstrated therapeutic equivalence to the twice-daily Austedo formulation.

For some patients living with the conditions “treatment adherence can be a challenge that this new once-daily dosing option can help to address,” the company said.

Teva plans to launch Austedo XR in the U.S. later this year.